KEYWORDS:
AAV, adeno-associated virus; CO, cardiac output; CRF, corticotropin-releasing factor; CRHR, corticotropin-releasing hormone receptor; CaMKII, Ca2+/calmodulin-dependent protein kinase II; EDD, end-diastolic diameter; EF, ejection fraction; ESD, end-systolic diameter; ESPVR, end-systolic pressure-volume relationship; HF, heart failure; IP, intraperitoneal; IV, intravenous; LV, left ventricle/ventricular; PKA, protein kinase A; RYR2, ryanodine receptor 2; SERCA2a, sarco/endoplasmic reticulum Ca2+-ATPase; Tau, time constant of left ventricular pressure decline; UCn2, urocortin 2; UCn3, urocortin 3; VCFc, velocity of circumferential fiber shortening corrected for heart rate; adeno-associated virus; cAMP, 3′,5′-cyclic adenosine monophosphate; contractile function; diastolic function; gc, genome copies; gene therapy; insulin sensitivity